Patrick Julier

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Susan Dutton, David Ferry, Jane Blazeby et al. · The Lancet Oncology · 2014 · 330 citations · Full text

Medicine, Oncology, Pharmacology +6

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Rachel Kerr, Sharon Love, Eva Segelov et al. · The Lancet Oncology · 2016 · 149 citations

Medicine, Oncology, Pharmacology +11

Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer

David J. Kerr, Janet Dunn, M. J. S. Langman et al. · New England Journal of Medicine · 2007 · 134 citations · Full text

Medicine, Oncology, Pharmacology +11

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at <i>DPYD</i> and a putative role for <i>ENOSF1</i> rather than <i>TYMS</i>

Dan Rosmarin, Claire Palles, Alistair T. Pagnamenta et al. · Gut · 2014 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial

Rachel Midgley, Christopher C. McConkey, Elaine Johnstone et al. · Journal of Clinical Oncology · 2010 · 99 citations · Full text

Medicine, Oncology, Pharmacology +15